Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q2 2026 · 10-Q
Revenue$35.00M$35.00Mno prior Q2 2025 on file Net Income$27.90M$27.90MN/M vs Q2 2025 EPS Diluted$0.89$0.89N/M vs Q2 2025 Operating Income$27,565,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,657,000— Margins · derivedOperating margin78.8%
Net margin79.7%
ended Jun 30, 2026 · filed Aug 7, 2026 · 38 d after period end